Renowned Japanese immunologist Dr Teruko Ishizaka passed away in June at the age...
- Understanding allergic reactions: chronicling the work of Dr Teruko Ishizaka
- Progress made in developing first Chlamydia vaccine
- Psoriasis Action Month: using genetics to improve drug development
- Sanofi’s Dupixent met study endpoints in children with atopic dermatitis
- Verona announces positive results for DPI form of COPD drug
Understanding allergic reactions: chronicling the work of Dr Teruko Ishizaka
Renowned Japanese immunologist Dr Teruko Ishizaka passed away in June at the age of 92. She has been credited with co-discovering IgE, a novel class of antibodies related to allergic reactions, changing the allergy field forever. Allie Nawrat takes a look at the life and achievements of this trailblazing, female scientist.
CureVac and Yale University to develop mRNA-based lung therapies
Biopharmaceutical firm CureVac has signed a collaborative research agreement with US-based Yale University to discover new therapeutic candidates for the treatment of pulmonary diseases.
Boehringer partners with MD Anderson on virtual R&D centre
Boehringer Ingelheim has collaborated with The University of Texas MD Anderson Cancer Center to create a joint Virtual Research and Development Center focused on oncology research.
Progress made in developing first Chlamydia vaccine
Researchers from Statens Serum Institut (SSI), Denmark, and Imperial College London have published promising results from the first clinical trial of a vaccine for Chlamydia, the most common sexually transmitted disease.
Psoriasis Action Month: using genetics to improve drug development
The role of a patient’s genes in causing inflammatory skin condition psoriasis has been largely accepted in the medical community over the past few decades. This has led to significant research into precisely which genes are associated with the condition and how this understanding can better inform drug development, as well as ensure there are effective treatments for more patients.
Sonnet BioTherapeutics agrees to buy Relief Therapeutics
Biotechnology company Sonnet BioTherapeutics has agreed to acquire all outstanding shares of Relief Therapeutics under a binding share exchange agreement with Relief Therapeutics Holding.
Indolent Non-Hodgkin’s Lymphoma: Roche Dominates Landscape
Roche’s Rituxan with or without chemotherapy is the standard-of-care regimen against which other agents are compared
UF researchers focus on new drug candidate Apratoxin S4 to treat vision loss
Researchers from the University of Florida (UF) College of Pharmacy have announced a partnership to focus on a new drug candidate Apratoxin S4 as a new method to prevent or treat vision loss.
Pharmaceutical Challenges Aided by Laboratory Powder X-ray Diffraction
This white paper explores a number of ways that today's modern, laboratory-based powder x-ray diffraction (PXRD) instrumentation and advanced software can greatly assist pharmaceutical scientists in their quest to develop high-quality, stable products and accelerate their speed-to-market.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.